{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=29",
    "query": {
      "intervention": "Genotyping",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 732,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T09:30:30.872Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01482390",
      "title": "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Mericitabine",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2011-11-30",
      "completion_date": "2014-01-31",
      "has_results": false,
      "last_update_posted_date": "2017-04-24",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482390"
    },
    {
      "nct_id": "NCT03464084",
      "title": "Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glucose",
        "Circadian Rhythm",
        "Melatonin",
        "Genes",
        "Light"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "melatonin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "bright light",
          "type": "OTHER"
        },
        {
          "name": "dim light",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-17",
      "completion_date": "2022-07-19",
      "has_results": false,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03464084"
    },
    {
      "nct_id": "NCT00200967",
      "title": "Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "salmeterol",
          "type": "DRUG"
        },
        {
          "name": "beclomethasone HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 87,
      "start_date": "2004-12",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 7,
      "location_summary": "San Diego, California • San Francisco, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00200967"
    },
    {
      "nct_id": "NCT01628692",
      "title": "Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Simeprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2012-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01628692"
    },
    {
      "nct_id": "NCT01384383",
      "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GS-5885",
          "type": "DRUG"
        },
        {
          "name": "GS-9451",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 248,
      "start_date": "2011-08",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-03",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384383"
    },
    {
      "nct_id": "NCT01675427",
      "title": "A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Interleukin 28B testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4766,
      "start_date": "2011-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 1,
      "location_summary": "Alexandria, Virginia",
      "locations": [
        {
          "city": "Alexandria",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01675427"
    },
    {
      "nct_id": "NCT02378961",
      "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "VOX",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2015-02-16",
      "completion_date": "2016-01-26",
      "has_results": true,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 31,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378961"
    },
    {
      "nct_id": "NCT03015610",
      "title": "Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma",
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "commercially available lansoprazole",
          "type": "DRUG"
        },
        {
          "name": "matched placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason Lang, M.D., M.P.H.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2017-10-31",
      "completion_date": "2024-01-18",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015610"
    },
    {
      "nct_id": "NCT02717949",
      "title": "Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Disease"
      ],
      "interventions": [
        {
          "name": "sofosbuvir/ledipasvir",
          "type": "DRUG"
        },
        {
          "name": "sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-02-25",
      "completion_date": "2017-07-18",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 3,
      "location_summary": "New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02717949"
    },
    {
      "nct_id": "NCT03038763",
      "title": "Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Eligibility Screening",
          "type": "OTHER"
        },
        {
          "name": "HCV test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-05-11",
      "completion_date": "2019-06-30",
      "has_results": false,
      "last_update_posted_date": "2019-07-17",
      "last_synced_at": "2026-10-22T09:30:30.872Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038763"
    }
  ]
}